These findings demonstrated that MBNL1-AS1 could competitively bind to miR-221-3p, which then targeted CDKN1B, potentially contributing to the malignancy of the PC cells and PCSCs. The gene discussed is CDKN1B; the disease is pachyonychia congenita.